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With the aging US population, demographic shifts, and obesity epidemic, there is potential for further exacerbation of the
current liver donor shortage. We aimed to project the availability of liver grafts in the United States. We performed a second-
ary analysis of the Organ Procurement and Transplantation Network database of all adult donors from 2000 to 2012 and
calculated the total number of donors available and transplanted donor livers stratified by age, race, and body mass index
(BMI) group per year. We used National Health and Nutrition Examination Survey and Centers for Disease Control and Pre-
vention historical data to stratify the general population by age, sex, race, and BMI. We then used US population age and
race projections provided by the US Census Bureau and the Weldon Cooper Center for Public Service and made national
and regional projections of available donors and donor liver utilization from 2014 to 2025. We performed sensitivity analyses
and varied the rate of the rise in obesity, proportion of Hispanics, population growth, liver utilization rate, and donation after
cardiac death (DCD) utilization. The projected adult population growth in the United States from 2014 to 2025 will be 7.1%.
However, we project that there will be a 6.1% increase in the number of used liver grafts. There is marked regional hetero-
geneity in liver donor growth. Projections were significantly affected by changes in BMI, DCD utilization, and liver utilization
rates but not by changes in the Hispanic proportion of the US population or changes in the overall population growth. Over-
all population growth will outpace the growth of available donor organs and thus potentially exacerbate the existing liver graft
shortage. The projected growth in organs is highly heterogeneous across different United Network for Organ Sharing
regions. Focused strategies to increase the liver donor pool are warranted. Liver Transpl 21:855-863, 2015. VC 2015
AASLD.
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Liver transplantation (LT) is a lifesaving therapy for
patients with end-stage liver disease and hepatocellu-
lar carcinoma. Over the last decade, there has been a
decrease in the availability of donor organs for
deceased donor LT in the United States, and this has
resulted in a plateau in the number of LTs per-
formed.1 The absolute number of organ donors has
steadily increased over the years; however, there has
not been a commensurate increase in the number of
liver donors. The principal cause of this trend has
been a decrease in the utilization of grafts, partially
due to an increase in the number of graft discards.2
This plateau has profound implications because the
decrease in donor availability has exacerbated the dis-
parity in the number of patients listed for LT and LTs
performed.3 This has resulted in prolonged waiting
times for LT and higher rates of wait-list dropout due
to patient death or a deteriorating medical condition.4
More than 20% of patients listed for LT will drop off
the wait list while they are awaiting LT.5 Attempts to
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remedy this by increasing the donor pool by utiliza-
tion of extended criteria donors [older donors, donors
with fatty liver disease, and donation after cardiac
death (DCD) donors] have resulted in inferior post-
transplant outcomes and decreased utilization.6,7 In
addition, regulatory policy changes such as increased
scrutiny of post-LT patient outcomes may have led
transplant centers to become more risk-averse toward
marginal grafts over time.8
The other reasons behind the decrease in liver donor
utilization are multifactorial and include the aging
population, the obesity epidemic, and the increased
prevalence of diabetes.2 The US population is
expected to continue to age with projected demo-
graphic trends, and this will likely exacerbate the
availability of donors.9-11 Older donors can result in
inferior graft outcomes, particularly in hepatitis C–
positive recipients.12
Recent evidence suggests that the obesity and dia-
betes epidemics in the United States have plateaued
in recent years; however, donor obesity and diabetes
account for a large portion of the drop in liver utiliza-
tion from 2004 to 2010.2,13,14 The impact of obesity
on donor utilization is largely a result of hepatic stea-
tosis, with higher percentages of steatosis limiting the
ability to conduct LT because of poor graft out-
comes.15 The correlation between obesity and liver
steatosis is differential on the basis of race/ethnicity.
For example, when one controls for the patient body
mass index (BMI), African Americans have lower rates
of significant hepatic steatosis than other subgroups,
whereas Latinos have higher rates of significant stea-
tosis.16 Therefore, changes in the racial make-up of
the US population will also affect donor organ avail-
ability over the next decade.
There are few data on the implications of demo-
graphic trends in the United States for the utilization
of donors in the United States over the next decade.
Although there is a common perception that organ
availability is getting worse, there are few objective
data to quantify expected organ availability. There-
fore, we aimed to use data on expected demographic
trends in the United States and past donor utilization
to make projections of donor utilization for LT in the
United States over the next decade. We hypothesize
that liver donor availability will continue to dispropor-
tionately decrease because of demographic trends in
the United States.




We used data from the Centers for Disease Control
and Prevention (CDC) on total population statistics
from 2000 to 2012, which were stratified by age, sex,
and race. The race/ethnicity categories included
white, black, Hispanic/Latino, and other.17 Data from
the US Census Bureau were used to obtain the popu-
lation estimates by state from 2000 to 2012. We used
2 data sets from the US Census Bureau: (1) intercen-
sal estimates of the resident population by 5-year age
groups, sex, race, and Hispanic origin for states and
the United States from April 1, 2000 to July 1, 2010
and (2) annual state resident population estimates for
6 race groups by age, sex, and Hispanic origin from
April 1, 2010 to July 1, 2012. We then stratified these
data by race, sex, and age group (18-34, 34-50, 50-
64, and 65-84 years) and segregated them on the
basis of the 11 regions established by United Network
for Organ Sharing (UNOS). The 18- to 34-year-old age
group of our models overlapped 2 age groups of the
US Census Bureau data set from 2000 to 2010; con-
sequently, the 18- to 34-year-old age group by region
was estimated on the basis of the proportion of the
remaining age groups by region (34-50, 50-64, and
65-84 years) of the total population of the 34- to 84-
year-old age groups across all regions.18
Historical BMI Data
We used data from the National Health and Nutrition
Examination Survey (NHANES) from 1999 to 2010 to
stratify historical population data from the CDC by BMI,
sex, and race.19 The NHANES data had to be adjusted to
match our modeling. For example, the race/ethnicity
groups did not include “other.” Given the overall obesity
prevalence, the prevalence for non-Hispanic whites,
non-Hispanic blacks, and Hispanics, and sample sizes
of the relevant populations, we back-calculated what
the prevalence of obesity would have to be for the “other”
groups. Additionally, the NHANES reports data by the
age groups of 20 to 39, 40 to 59, and 601 years, but our
model groups ages into 18 to 34, 34 to 50, 50 to 64, and
65 to 84 years. We imputed the obesity rates for the
NHANES age groups and our predefined age groups.19
Donor Utilization Data
We performed a secondary analysis of the Organ Pro-
curement and Transplantation Network database
from 2000 to 2012. We determined the utilization
rates of whole and split livers for all donors with at
least 1 organ transplanted. We also calculated the uti-
lization as a percentage of the overall population per
year. We constructed utilization tables by year strati-
fied by age groups, BMI (<30 or 30 kg/m2), sex, and
race/ethnicity.
Population Age, Sex, and Race Projections
Population projections in the United States for 2014 to
2025 were derived from the data from the US Census
Bureau, which are stratified by age, sex, and race.20 For
the base case, we used the middle series projections.
State Population Projection
We used data from the University of Virginia’s Weldon
Cooper Center for Public Service on state population
projections from 2010 to 2030 to estimate population
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projection for each UNOS region. The population pro-
jections were stratified by race, sex, and age group.
Because population projections by state included
information only for 2010, 2020, and 2030, the popu-
lation projections from 2014 to 2019 and from 2021
to 2025 were estimated under the assumption of lin-
ear growth.21
Projection Development
We developed projections of donor availability from
2014 to 2025 by determining the US population–
based rate of donation (donors transplanted/total
population) per year and used the average donation
rate from 2008 to 2012 stratified by age group (18-34,
34-50, 50-64, and 65-84 years old), race/ethnicity
(white, black, Hispanic, and other), sex, and BMI (<30
or 30 kg/m2). We then used the historic liver utiliza-
tion rates (liver donors/total donors) to project future
donor utilization. We used the average utilization from
2008 to 2012 and the best (2004) and worst (2012)
liver utilization from 2000 to 2012 to conduct projec-
tions on liver donor availability. For regional projec-
tions, we used the historical regional rate of donation
(donors transplanted/regional total population) per
year and used the average donation rate from 2008 to
2012 to make regional projections on donor availabil-
ity. All analyses were conducted with SAS (version
9.4; SAS Institute, Inc., Cary, NC), Mathcad (version
15.0; PTC, Needham, MA), and Microsoft Excel (ver-
sion 2013; Microsoft Corp., Redmond, WA).
Sensitivity Analysis
We performed 4 separate sensitivity analyses; we var-
ied the proportion of obese adults, proportion of His-
panic adults, and overall US adult population growth
over the projection period, and we varied the change
in the liver utilization rate over time. For the first sen-
sitivity analysis, we varied the rate of BMI changes
over the next decade. The ranges for the sensitivity
analysis of BMI were derived from the average annual
rate of increase in the US population BMI in the obese
range (30 kg/m2) from 1999 to 2010, which was
approximately 0.75% per year.19 The ranges for the
sensitivity analysis for the proportion of Hispanic
adults were obtained from US Census Bureau high
and low race/ethnicity projections.20 We chose to
focus the sensitivity analysis on the proportion of US
Hispanics because this population is projected to be
the most dynamic in the United States over the com-
ing decade with respect to other racial/ethnic
groups.20 For the overall population growth sensitivity
analyses, we used the high and low population projec-
tions from the US Census Bureau data.20 Because
liver utilization has been decreasing over the last 7
years and there has not been a clear nadir in utiliza-
tion, we conducted a sensitivity analysis and varied
the rate of liver utilization. We calculated the average
change in liver utilization from 2007 to 2012, which
was a mean decrease of 0.72% per year. We then con-
ducted our projections by increasing or decreasing
the liver utilization by 0.72% per year from the 2012
rate. For the sensitivity analysis of DCD donor projec-
tions, we modeled liver utilization. There has been an
increase in total DCD donors; however, there has
been a decline in liver utilization from 2007 to 2012
of 3.94% per year. We modeled the average and
increasing or decreasing utilization of livers from DCD
donors by 3.94% from the 2012 rate. The overall DCD
donation rate as a proportion of the population was
averaged from 2008 to 2012.
Monte Carlo Simulation
We performed a Monte Carlo simulation in order to
measure the combined impact of uncertainty in popu-
lation projections, population BMI, donation rates,
and utilization rates on projected donors. We defined
each input variable as a distribution. The population
projections were defined as normal distributions with
the mean of the middle series projection and the
standard deviation as one-quarter of the difference
between the high and low projections. The fractions of
the population with a BMI>30 kg/m2 by age, sex,
and race were defined as normal distributions with
the means and 95% confidence intervals as reported
in the NHANES study.19 Donation and utilization
rates were drawn from the annual empirical distribu-
tions of rates from 2000 to 2012. More details on the
distributions used are in Supporting Text 1. We cre-
ated projections with 10,000 Monte Carlo simulation
iterations. The Monte Carlo simulation was executed
with SimVoi (version 3.03; TreePlan Software, San
Francisco, CA).
RESULTS
The historical trends in total donors and liver donor
utilization are shown in Table 1. The number of
cadaveric liver grafts used increased 49.3% from 2000
to 2006 and then slightly decreased 3.0% from 2006
to 2012. The proportion of liver grafts used per
100,000 US population plateaued in 2006 at 2.79/
100,000 population and decreased since then 9.0% to
2.54/100,000 population in 2012. The utilization of
livers from all donors has trended downward since
2004 from 87.92% to 81.72%% in 2012. The overall
demographic trends of liver donors (race, age, and
sex) did not change dramatically from 2000 to 2012
(data not shown). DCD liver utilization peaked in
2005 at 68.5%; however, there has been a steady
decrease in recent years, with the 2012 liver utiliza-
tion rate being 36.5%. The overall number of DCD
liver donors has remained relatively stable, with 358
livers used in 2005 and in 2012, because of growth in
overall DCD donation.
Figure 1 shows the utilized liver donor projections
with the best (2004), worst (2012), and average liver
utilization rates from 2008 to 2012. The worst liver
utilization rates have been seen in recent years, and
this is reflected in the projection curves. All the curves
show a steady increase in the expected number of
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liver grafts available from 6129 (range, 6047-6462) in
2014 to 6500 (range, 6429-6833) in 2025.
Table 2 shows the projections in total adult US pop-
ulation growth versus projection in donor growth. The
projected US population growth will consistently out-
strip the growth in potential liver donors from 2014 to
2025. In total, the projected adult population growth
(age, 18-75 years) in the United States from 2014 to
2025 will be 7.1%. This age range is considered
acceptable at most centers in the United States for
receiving LT. However, we project that there will be a
5.8% increase in the number of available donors and
a 6.1% increase in the number of used liver grafts.
The number of donors per 100,000 population will
steadily drop over time, but the absolute number of
donors will grow because of projected population
growth.
The projections stratified by regions show differen-
tial projected growth of donors depending on the
UNOS region, and they reflect regional changes in
population growth (Table 3). The region with the most
projected growth in liver donors is region 3 (10.8%),
whereas region 10 is projected to have a decline in
liver donors (22.0%).
Figure 1. Projections of liver organ availability according to base-case and high-low liver utilization.















2000 4113 2.00 4966 82.82
2001 4251 2.04 5082 83.65
2002 4473 2.13 5250 85.20
2003 4863 2.29 5549 87.64
2004 5420 2.52 6165 87.92
2005 5869 2.70 6684 87.81
2006 6141 2.79 7035 87.29
2007 6095 2.74 7144 85.32
2008 5964 2.65 7096 84.05
2009 5942 2.61 7101 83.68
2010 5864 2.55 7093 82.67
2011 5963 2.57 7233 82.44
2012 5956 2.54 7288 81.72
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The results of the sensitivity analysis for BMI are
shown in Fig. 2A. The results show that donor avail-
ability is sensitive to increases or decreases in the
proportion of adults with a BMI>30 kg/m2, with a
6.2% range in projected liver donors. The results for
the sensitivity analysis for changes in the Hispanic
proportion of the US population are shown in Fig. 2B.
Changes in the Hispanic population do not result in a
dramatic change in the projected number of liver
grafts, with a 0.62% range in projected liver donors.
The impact of changes in total US population growth
is shown in the sensitivity analysis in Fig. 2C. The
availability of donors is also fairly insensitive to
changes in these parameters, with a 1.4% range in
projected liver donors. Figure 2D shows the sensitivity
analysis of changes in the liver utilization rate over
time. With this projection, the 2025 utilization would
be 90.12% in the utilization growth scenario and
73.32% in the utilization decline scenario. The results
show that liver donor availability is sensitive to utili-
zation, with a 19.6% range at the end of the projection
time period. The sensitivity analysis for DCD liver uti-
lization is shown in Fig. 2E. The base case shows
declining utilization of DCD livers under the assump-
tion of a constant utilization rate. With increasing or
decreasing utilization, mirroring trends from 2007 to
2012, we see marked changes in the available DCD
liver donors, and they reflected the dramatic changes
in utilization seen between 2007 and 2012.
The Monte Carlo simulation is shown in Fig. 3.
Incorporating uncertainty in all the input projection
variables, the projections using the Monte Carlo simu-
lation are very similar to our base-case projections
shown in Fig. 1.
















2014 0.7 6129 0.7 0.9 2.57
2015 0.6 6168 0.6 0.8 2.56
2016 0.6 6207 0.6 0.8 2.56
2017 0.6 6245 0.6 0.8 2.55
2018 0.6 6284 0.6 0.8 2.54
2019 0.6 6320 0.5 0.6 2.54
2020 0.5 6351 0.5 0.6 2.53
2021 0.5 6383 0.5 0.6 2.52
2022 0.5 6413 0.4 0.6 2.51
2023 0.5 6442 0.4 0.3 2.51
2024 0.5 6471 0.4 0.4 2.50
2025 0.4 6500 0.4 0.4 2.49
Cumulative 6.1 1371 5.8 7.1
























2014 177 829 1098 490 763 177 477 458 295 541 756
2015 178 833 1110 494 769 178 479 460 297 541 762
2016 178 837 1122 498 775 178 480 462 299 541 767
2017 178 840 1134 502 781 179 481 464 300 540 773
2018 178 843 1146 507 787 180 482 466 302 540 778
2019 179 846 1157 511 793 181 483 467 304 539 783
2020 179 849 1167 515 798 181 483 469 305 538 787
2021 179 852 1177 518 803 182 484 470 307 536 791
2022 178 854 1187 522 808 182 484 471 309 535 795
2023 178 856 1197 525 813 183 484 472 310 534 799
2024 178 858 1207 528 818 184 484 474 311 532 803
2025 178 860 1216 532 824 185 484 475 313 530 807
% change 0.4 3.7 10.8 8.6 7.9 4.3 1.5 3.7 6.1 22.0 6.7
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DISCUSSION
LT remains the best lifesaving therapy for patients
with end-stage liver disease and hepatocellular carci-
noma; however, the ability to perform transplantation
is limited by donor availability. Although there is a
perception that donor availability will continue to
worsen with future demographic changes in the US
population, this has not been objectively studied. We
found that although the donor population will
increase over the next 12 years, general population
growth will outstrip projected donor growth and thus
potentially exacerbate the donor shortage and
increase wait times for LT nationally. The projected
discordance between population growth and liver
Figure 2. (A) BMI sensitivity analysis, (B) Hispanic population sensitivity analysis, (C) population growth sensitivity analysis, (D) liver
utilization sensitivity analysis, and (E) DCD liver utilization sensitivity analysis.
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donor growth is modest at 1%; however, the projec-
tions indicate that there is no relief in sight for the
current donor shortage. There is wide regional vari-
ability in the projections. Although some regions (3, 4,
and 5) are expected to have >7% growth in liver
donors, regions 1, 6, and 10 are projected to have
marginal or negative projected growth. There are pro-
found implications for these regions that should be
taken into account with future allocation policy and
with any redistricting proposals that will be
considered.
The sensitivity analyses showed that the projections
were significantly affected by changes in BMI, liver,
and DCD utilization rate but not by changes in the
Hispanic proportion of the US population or changes
in the overall population growth. Increases in the pro-
portion of obese adults or decreases in liver utilization
will further limit the availability of LTs. However, any
intervention that can increase utilization will have a
large impact on liver availability. For the DCD analy-
sis, there is a wide projected range because of the
marked changes in utilization in recent years.
Strategies to increase the donor pool are warranted
to help alleviate the anticipated shortage in donors to
decrease wait-list mortality. These include increasing
donor enrollment and public awareness regarding
organ donation,22,23 optimizing the processes of organ
retrieval and allocation,24 and using technologies to
increase the viability of organs with prolonged cold
ischemia times and DCD donor organs.25 In addition,
regions with poor expected growth could implement
more concerted efforts to increase the overall donation
rate to help alleviate the projected shortages in their
regions. Otherwise, we do not anticipate a major
expansion in the utilization of DCD livers because of
the inferior outcomes seen with these grafts, and our
base case shows that the number of DCD livers trans-
planted will continue to steadily decline.7 Expansion
of living donor LT could also help alleviate the pro-
jected shortage; however, risks to donors remain a
concern in the United States.26,27 Broader regulatory
changes that may lead to variance in risk aversion
with respect to marginal grafts are more difficult to
project; however, with the increased focus on out-
comes and quality of care and links to reimburse-
ment, we anticipate that risk aversion may worsen in
the future.28-30 In addition, there is uncertainty
regarding the proportion of DCD donors in the future.
Currently, DCD donors account for a small minority
of organ donors; however, future increases would neg-
atively affect liver graft availability.2 We assumed
maintenance of the current proportion of DCD donors
in the future in our sensitivity analysis, but changes
in utilization will markedly affect the number of DCD
livers available. Any technologies to improve outcomes
of transplanted DCD livers that lead to improved utili-
zation could more than double the projected amount
of livers available over the time period in this study.
Projecting the need for LT in the future is more
uncertain because of the rapidly changing landscape
of chronic hepatitis C and the emergence of nonalco-
holic fatty liver disease. There is the possibility that
the number of patients requiring transplantation will
decrease, and this will partially alleviate the donor
shortage despite our predictions. With new potent
antiviral agents against hepatitis C under develop-
ment and recently approved,31 the need for LT in this
population will likely diminish, although access to
and the cost of these medications remain concerns.32
However, nonalcoholic fatty liver disease–related cir-
rhosis and hepatocellular carcinoma have emerged as
leading indications for LT, and continued growth may
Figure 3. Monte Carlo simulation of liver organ availability.
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cause further expansion of the LT recipient wait
list.33,34 The results of our study must be contextual-
ized with the need for organ transplants in the future,
and further modeling of the demand side of LT in the
coming years is warranted.
There are many strengths and weaknesses of our
study. We compiled unique data elements from many
sources to complete our projections, and thus, many
of our input variables are dependent on single-source
data. The projections of organ availability assume no
major changes in donor availability or breakthroughs
in procurement technologies that could dramatically
increase liver utilization rates. We accounted for incre-
mental changes that would affect liver utilization with
our final sensitivity analysis, and we varied the utili-
zation rate over time. A significant breakthrough
resulting in major changes in utilization could signifi-
cantly alter these projections. However, we do not
anticipate approval and widespread adoption of new
technologies during the relatively short time horizon
of this study. In addition, BMI is an imperfect mea-
sure and has decreased validity in elderly popula-
tions, in part because of sarcopenic obesity.35
Increased hepatic steatosis at lower BMIs in the
elderly population may lead to lower than predicted
availability of liver allografts. We also did not account
for any other potential changes in public policy such
as implied consent for donation that may increase the
pool of donors available.36
In conclusion, we project further exacerbation of the
donor shortage for LT over the next decade, with total
population growth outstripping the growth in poten-
tial donors. There are marked and important regional
differences in the projected growth that must be con-
sidered in regional planning and in allocation policy.
Changes in the proportion of obese US adults over the
next decade will significantly affect the number of
available donors. This study can serve as an objective
guide so that steps can be taken for future planning
to help alleviate the mismatch between liver donors
and recipients to prevent wait-list dropout.
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